Pseudoprogression in patients on immunotherapy
D. I. Yudin,
K. K. Laktionov,
K. A. Sarantseva,
V. V. Breder,
E. V. Reutova,
O. I. Borisova,
M. S. Ardzinba https://doi.org/10.21518/2079-701X-2019-10-10-14
Abstract
Now the number of patients receiving immunotherapy with checkpoint inhibitors is growing. At the same time, clinicians increasingly encounter such a clinical phenomenon as pseudoprogression. Nowadays we have no radiological evidences of pseudoprogression. The every such case requires an individual decision.
About the Authors
D. I. Yudin
Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.
Russian Federation
Russian Federation
Cand. of Sci. (Med), Senior Researcher at the Clinical Biotechnologies Department of the Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.
K. K. Laktionov
Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.
Russian Federation
Russian Federation
Dr. of Sci. (Med), Deputy Director for Medical Work of the Research Institute of Clinical Oncology, Head of the Department of Chemotherapy No. 1 of the Thoracoabdominal Department (Clinical Biotechnologies) of the Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.
K. A. Sarantseva
Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.
Russian Federation
Russian Federation
Cand. of Sci. (Med), oncologist of the Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.
V. V. Breder
Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.
Russian Federation
Russian Federation
Dr. of Sci. (Med), Leading Researcher of the Department of Chemotherapy No. 1 of the Thoracoabdominal Department (Clinical Biotechnologies) of the Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.
E. V. Reutova
Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.
Russian Federation
Russian Federation
Cand. of Sci. (Med), Senior Researcher at the Surgical Department No. 13 (Clinical Biotechnologies) of the Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.
O. I. Borisova
Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.
Russian Federation
Russian Federation
Oncologist of the Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.
M. S. Ardzinba
Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.
Russian Federation
Russian Federation
Cand. of Sci. (Med), Oncologist, Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.
References
1. Chiou V.L., Burotto M. Pseudoprogression and Immune-Related Response in Solid Tumors. J Clin Oncol. 2015 Nov 1;33(31):3541-3.
2. Eisenhauer E.A., Therasse P., Bogaerts J. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer. 2009 Januar;45(2):228–47.
3. Wolchok J.D., Hoos A., Bohnsack O. et al. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-
4. Related Response Criteria. Clin Cancer Res. 2009;15(23) December 1, 2009.
5. Nishino M., Gargano M., Suda M., Ramaiya N.H., Hodi F.S. Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab? J Immuno ther Cancer. 2014; 2: 17. doi:10.1186/2051-1426-2-17.
6. Nishino M. et al. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res. 2013 Jul 15;19(14):3936-43.
7. Nishino M., Ramaiya N.H., Chambers E.S. et al. Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients. J Immunother Cancer. 2016;4:84.
8. Seymour L., Bogaerts J., Perrone A. et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18:e143–52.
9. Hodi F., Ballinger M., Lyons B. et al. Immune- Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. J Clin Oncol. 2018;36:850-858.
10. Brahmer J.R., Tykodi S.S., Chow L.Q. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–2465
11. Topalian S.L., Hodi F.S., Brahmer J.R. et al. Safety, activity, and immune correlates of anti- PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–2454.
12. Topalian S.L., Sznol M., McDermott D.F. et al. Survival, durable tumor remission, and longterm safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32:1020–1030.
13. Wolchok J.D., Kluger H., Callahan M.K. et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122–133.
14. Hodi F.S., Ribas A., Daud A. et al. Evaluation of immune-related response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. J Clin Oncol. 2014;(suppl 15s):32. abstr 3006.
15. Wolchok J.D., Hamid O., Ribas A. Atypical patterns of response in patients (pts) with metastatic melanoma treated withpembrolizumab (MK-3475) in KEYNOTE-001. J Clin Oncol. 2015;33(15 supplement):3000. doi: 10.1200/jco.2015.33.15_suppl.3000.
16. Nishino M., Dahlberg S., Adeni A. et al. Tumor Response Dynamics of Advanced Non–small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome. Clin Cancer Res. 2017 October 1;23(19). doi: 10.1158/1078-0432.CCR-17-1434.
17. Gettinger S.N., Horn L., Gandhi L., Spigel D.R., Antonia S.J., Rizvi N.A. et al. Overall survival and long-term safety of nivolumab (Anti- Programmed Death 1 Antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2015;33: 2004–12.
18. Grierson P., Crites D., Ruzinova M. et al. Distinct Clinical and Magnetic Resonance Features of Metastatic Hepatocellular Carcinoma Treated With Pembrolizumab: A Case Report of Late Response After Pseudoprogression. Hepatology Communications. 2018;2:148-151.
19. Sweis R., Zha Y. et al. Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer. Journal for ImmunoTherapy of Cancer. 2018;6:24. doi: 10.1186/s40425-018-0334-x.
20. Kolla B.C., Patel M.R. Recurrent pleural effusions and cardiac tamponade as possible manifestations of pseudoprogression associated with nivolumab therapy – a report of two cases. J Immunother Cancer. 2016;4:80.
Review
For citations:
Yudin DI, Laktionov KK, Sarantseva KA, Breder VV, Reutova EV, Borisova OI, Ardzinba MS. Pseudoprogression in patients on immunotherapy. Meditsinskiy sovet = Medical Council. 2019;(10):10-14. (In Russ.) https://doi.org/10.21518/2079-701X-2019-10-10-14
Views:
1250
Email this article 